- Drug Pipelines
- December 2024
- 60 Pages
Global
From €1432EUR$1,500USD£1,199GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- May 2024
- 135 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- June 2024
- 200 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Clinical Trials
- November 2024
- 177 Pages
Global
From €3293EUR$3,450USD£2,759GBP
- Report
- August 2022
Global
From €754EUR$790USD£632GBP
- Report
- December 2022
- 200 Pages
Global
From €1909EUR$2,000USD£1,599GBP
The Dengue Fever Drug market is a subset of the larger Infectious Diseases Drugs market. Dengue Fever is a mosquito-borne viral infection that is endemic in tropical and subtropical regions. It is a leading cause of illness and death in many countries. Treatment for Dengue Fever is largely supportive, but there are a few drugs that have been developed to treat the disease. These drugs are typically administered orally or intravenously and are used to reduce the severity of symptoms and shorten the duration of the illness.
The market for Dengue Fever Drugs is relatively small, but it is growing as the disease continues to spread. There are a number of companies that are developing and marketing drugs for the treatment of Dengue Fever, including Sanofi, Takeda, and GlaxoSmithKline. Other companies, such as Merck, are also researching potential treatments for the disease. Show Less Read more